Yesterday, Novartis released new data from its head-to-head CLARITY study that shows that its secukinumab (Cosentyx) was significantly more effective than ustekinumab (Stelara) in the treatment of psoriasis in delivering clear or almost clear skin at 12 and 16 weeks.
Yesterday, Novartis released new data from its head-to-head CLARITY study that shows that its secukinumab (Cosentyx) was significantly more effective than ustekinumab (Stelara) in the treatment of psoriasis in delivering clear or almost clear skin at 12 and 16 weeks.
Secukinumab is a targeted biologic therapy that inhibits IL-17A, a cytokine involved in inflammation of entheses.
The results of the CLARITY study show that 66.5% and 72.3% of patients treated with secukinumab (P <.0001) achieved both co-primary endpoints of a response of 90 on the Psoriasis Area and Severity Index (PASI90) and a score of score of 0/1 on the Investigator’s Global Assessment (IGA) (modified 2011), a 5-point tool used to evaluate plaque psoriasis severity, respectively. These results are compared with 47.9% and 55.4%, respectively, of patients treated with ustekinumab achieving PASI90 and IGA 0/1 (P <.0001).
In addition, all key secondary endpoints in the CLARITY study were met, and the safety profile of secukinumab was in line with its known safety profile. The newly released data support findings from the CLEAR study, which found secukinumab to be superior to ustekinumab in achieving sustained skin clearance at 52 weeks.
“These data add to the robust body of evidence supporting the use of Cosentyx to treat moderate to severe plaque psoriasis,” said Mark Lebwohl, MD, chairman of the Waldman department of dermatology at the Icahn School of Medicine at Mount Sinai Hospital in New York. “With these findings clinicians can have even greater confidence including Cosentyx in their treatment plans.”
To date, more than 125,000 patients worldwide have been prescribed secukinumab in the post-marketing setting across all indications. According to Novartis’ third quarter results in 2017, Cosentyx reached $556 million in net sales. Its fourth quarter 2017 results will be announced shortly.
Novartis also recently announced that it is initiating the SURPASS trial; SUPRASS is set to be a head-to-head clinical trial of secukinumab versus a proposed biosimilar adalimumab (referencing Humira and being developed by Sandoz, a Novartis division) in patients with ankylosing spondylitis. Positive results in this trial could potentially make secukinumab a top competitor for an increased share of the market for inflammatory disease treatment.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.